Evidence for residual SARS-CoV-2 in glioblastoma tissue of a convalescent patient
- PMID: 33994523
- DOI: 10.1097/WNR.0000000000001654
Evidence for residual SARS-CoV-2 in glioblastoma tissue of a convalescent patient
Abstract
Since coronavirus disease 2019 (COVID-19) swept all over the world, several studies have shown the susceptibility of a patient with cancer to COVID-19. In this case, the removed glioblastoma multiforme (GBM)-adjacent (GBM-A), GBM-peritumor and GBM-central (GBM-C) tissues from a convalescent patient of COVID-19, who also suffered from glioblastoma meanwhile, together with GBM-A and GBM tissues from a patient without COVID-19 history as negative controls, were used for RNA ISH, electron microscopy observing and immunohistochemical staining of ACE2 and the virus antigen (N protein). The results of RNA ISH, electron microscopy observing showed that SARS-CoV-2 directly infects some cells within human GBM tissues and SARS-CoV-2 in GBM-C tissue still exists even when it is cleared elsewhere. Immunohistochemical staining of ACE2 and N protein showed that the expressions of ACE2 are significantly higher in specimens, including GBM-C tissue from COVID-19 patient than other types of tissue. The unique phenomenon suggests that the surgical protection level should be upgraded even if the patient is in a convalescent period and the pharyngeal swab tests show negative results. Furthermore, more attention should be paid to confirm whether the shelter-like phenomenon happens in other malignancies due to the similar microenvironment and high expression of ACE2 in some malignancies.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Comprehensive Oncogenic Features of Coronavirus Receptors in Glioblastoma Multiforme.Front Immunol. 2022 Apr 6;13:840785. doi: 10.3389/fimmu.2022.840785. eCollection 2022. Front Immunol. 2022. PMID: 35464443 Free PMC article.
-
Comparison of RNA In Situ Hybridization and Immunohistochemistry Techniques for the Detection and Localization of SARS-CoV-2 in Human Tissues.Am J Surg Pathol. 2021 Jan;45(1):14-24. doi: 10.1097/PAS.0000000000001563. Am J Surg Pathol. 2021. PMID: 32826529
-
Nucleocapsid Protein of SARS-CoV-2 Upregulates RANTES Expression in A172 Glioblastoma Cells.Molecules. 2025 Feb 26;30(5):1066. doi: 10.3390/molecules30051066. Molecules. 2025. PMID: 40076291 Free PMC article.
-
Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones.Am J Physiol Heart Circ Physiol. 2021 Jan 1;320(1):H296-H304. doi: 10.1152/ajpheart.00755.2020. Epub 2020 Dec 4. Am J Physiol Heart Circ Physiol. 2021. PMID: 33275517 Free PMC article. Review.
-
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review.Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12609-12622. doi: 10.26355/eurrev_202012_24058. Eur Rev Med Pharmacol Sci. 2020. PMID: 33336781 Review.
Cited by
-
Comprehensive Oncogenic Features of Coronavirus Receptors in Glioblastoma Multiforme.Front Immunol. 2022 Apr 6;13:840785. doi: 10.3389/fimmu.2022.840785. eCollection 2022. Front Immunol. 2022. PMID: 35464443 Free PMC article.
-
Detection of SARS-CoV-2 RNA by In Situ Hybridization in Lung-Cancer Cells Metastatic to Brain and in Adjacent Brain Parenchyma.Pathogens. 2023 May 29;12(6):772. doi: 10.3390/pathogens12060772. Pathogens. 2023. PMID: 37375462 Free PMC article.
-
The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies.Cell Mol Biol Lett. 2022 Feb 2;27(1):10. doi: 10.1186/s11658-022-00311-1. Cell Mol Biol Lett. 2022. PMID: 35109786 Free PMC article. Review.
-
SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines.Cancers (Basel). 2023 Jan 19;15(3):632. doi: 10.3390/cancers15030632. Cancers (Basel). 2023. PMID: 36765590 Free PMC article.
-
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.Curr Treat Options Oncol. 2024 Jul;25(7):952-991. doi: 10.1007/s11864-024-01211-6. Epub 2024 Jun 19. Curr Treat Options Oncol. 2024. PMID: 38896326 Free PMC article. Review.
References
-
- Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21:335–337.
-
- Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020; 10:783–791.
-
- Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020; 21:e180.
-
- Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020; 6:1108–1110.
-
- Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020; 21:893–903.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous